Literature DB >> 16132947

Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.

M Ledl1, J Hohenecker, C Francesconi, I Roots, M F Bauer, M Roden.   

Abstract

AIMS/HYPOTHESIS: This report describes the case of a 75-year-old male type 2 diabetic Caucasian who was admitted to the clinical ward because of acute pain and cramps in both calf muscles.
MATERIALS AND METHODS: Neuromuscular function was assessed by electromyography and electroneurography of the right leg. An open biopsy was taken from the left vastus lateralis muscle for histological and histochemical analyses. Southern blotting was performed to detect defects in mitochondrial DNA and tRNA. Cytochrome P450 (CYP-P450) polymorphisms were analysed in blood cells.
RESULTS: Fifteen weeks before admission, the patient's lipid-lowering medication was switched from simvastatin to fenofibrate because of predominant hypertriglyceridaemia; this did not affect creatine kinase levels. Three weeks before admission, rosiglitazone was added to his existing metformin therapy because of worsening metabolic control. Upon admission, serum enzymes indicating myopathy were elevated (creatine kinase 6897 U/l, myoglobin 902 ng/ml) and kidney function was impaired (creatinine 0.116 mmol/l, blood urea nitrogen 2.3 mmol/l). Electrophysiology revealed myopathy and sensory polyneuropathy. Histology showed multiple damage of the myofibrillar architecture. There was no evidence of defects in mitochondrial DNA or tRNA. Furthermore, no functional limitations in CYP2C9, CYP2C19 and CYP2D6 were detected. Following withdrawal of the oral medication and intravenous hydration, clinical symptoms and laboratory parameters gradually decreased. CONCLUSIONS/
INTERPRETATION: Until more data from controlled trials are available, we recommend that combination therapy with fibrates and thiazolidinediones should be monitored frequently by measurements of serum creatine kinase and creatinine, specifically in patients with pre-existing nephropathy and polyneuropathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132947     DOI: 10.1007/s00125-005-1919-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  9 in total

1.  Fenofibrate monotherapy induced rhabdomyolysis.

Authors:  Billie J Barker; Roger R Goodenough; James M Falko
Journal:  Diabetes Care       Date:  2003-08       Impact factor: 19.112

2.  Acute rhabdomyolysis associated with troglitazone.

Authors:  M Yokoyama; Y Izumiya; M Yoshizawa; R Usuda
Journal:  Diabetes Care       Date:  2000-03       Impact factor: 19.112

Review 3.  Safety of statins: focus on clinical pharmacokinetics and drug interactions.

Authors:  Stefano Bellosta; Rodolfo Paoletti; Alberto Corsini
Journal:  Circulation       Date:  2004-06-15       Impact factor: 29.690

Review 4.  Thiazolidinediones.

Authors:  Hannele Yki-Järvinen
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

5.  Risk of adverse events with fibrates.

Authors:  Alawi A Alsheikh-Ali; Jeffrey T Kuvin; Richard H Karas
Journal:  Am J Cardiol       Date:  2004-10-01       Impact factor: 2.778

6.  Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  Andrew J Lewin; Mark S Kipnes; Luigi F Meneghini; Diane J Plotkin; Inna T Perevozskaya; Sukrut Shah; Darbie L Maccubbin; Yale B Mitchel; Jonathan A Tobert
Journal:  Clin Ther       Date:  2004-03       Impact factor: 3.393

7.  Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.

Authors:  Anne L Peters Harmel; David M Kendall; John B Buse; Patrick J Boyle; Albert Marchetti; Helen Lau
Journal:  Curr Med Res Opin       Date:  2004       Impact factor: 2.580

8.  Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.

Authors:  Mikko Niemi; Janne T Backman; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2004-09       Impact factor: 6.875

Review 9.  Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs).

Authors:  Roberto Scatena; Giuseppe E Martorana; Patrizia Bottoni; Bruno Giardina
Journal:  IUBMB Life       Date:  2004-08       Impact factor: 3.885

  9 in total
  5 in total

Review 1.  Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Authors:  Gillian M Keating; Katherine F Croom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  McArdle disease: a "pediatric" disorder presenting in an adult with acute kidney injury.

Authors:  Xixi Zhao; Angela Li; Madhu Soni; Michael J Muriello; Carolyn H Jones; William L Whittier
Journal:  CEN Case Rep       Date:  2017-06-28

3.  Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus.

Authors:  Sabina Semiz; Tanja Dujic; Barbara Ostanek; Besim Prnjavorac; Tamer Bego; Maja Malenica; Janja Marc; Adlija Causevic
Journal:  Bosn J Basic Med Sci       Date:  2010-11       Impact factor: 3.363

4.  Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazone.

Authors:  N L Julie; I M Julie; A I Kende; G L Wilson
Journal:  Diabetologia       Date:  2008-08-23       Impact factor: 10.122

Review 5.  Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.

Authors:  Nicola Tarantino; Francesco Santoro; Luisa De Gennaro; Michele Correale; Francesca Guastafierro; Antonio Gaglione; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Vasc Health Risk Manag       Date:  2017-02-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.